% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{RgioBrambilla:874445,
      author       = {Régio Brambilla, Cláudia and Veselinović, Tanja and
                      Rajkumar, Ravichandran and Mauler, Jörg and Orth, Linda and
                      Ruch, Andrej and Ramkiran, Shukti and Heekeren, Karsten and
                      Kawohl, Wolfram and Wyss, Christine and Kops, Elena Rota and
                      Scheins, Jürgen and Tellmann, Lutz and Boers, Frank and
                      Neumaier, Bernd and Ermert, Johannes and Herzog, Hans and
                      Langen, Karl‐Josef and Jon Shah, N. and Lerche, Christoph
                      and Neuner, Irene},
      title        = {m{G}lu{R}5 receptor availability is associated with lower
                      levels of negative symptoms and better cognition in male
                      patients with chronic schizophrenia},
      journal      = {Human brain mapping},
      volume       = {41},
      number       = {10},
      issn         = {1097-0193},
      address      = {New York, NY},
      publisher    = {Wiley-Liss},
      reportid     = {FZJ-2020-01446},
      pages        = {2762-2781},
      year         = {2020},
      abstract     = {Consistent findings postulate disturbed glutamatergic
                      function (more specifically a hypofunction of the ionotropic
                      NMDA receptors) as an important pathophysiologic mechanism
                      in schizophrenia. However, the role of the metabotropic
                      glutamatergic receptors type 5 (mGluR5) in this disease
                      remains unclear. In this study, we investigated their
                      significance (using [11C]ABP688) for psychopathology and
                      cognition in male patients with chronic schizophrenia and
                      healthy controls. In the patient group, lower mGluR5 binding
                      potential (BPND) values in the left temporal cortex and
                      caudate were associated with higher general symptom levels
                      (negative and depressive symptoms), lower levels of global
                      functioning and worse cognitive performance. At the same
                      time, in both groups, mGluR5 BPND were significantly lower
                      in smokers (F [27,1] = 15.500; p = .001), but without
                      significant differences between the groups. Our findings
                      provide support for the concept that the impaired function
                      of mGluR5 underlies the symptoms of schizophrenia. They
                      further supply a new perspective on the complex relationship
                      between tobacco addiction and schizophrenia by identifying
                      glutamatergic neurotransmission—in particularly
                      mGluR5—as a possible connection to a shared
                      vulnerability.},
      cin          = {INM-11 / INM-4 / JARA-BRAIN / INM-5},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-11-20170113 / I:(DE-Juel1)INM-4-20090406 /
                      $I:(DE-82)080010_20140620$ / I:(DE-Juel1)INM-5-20090406},
      pnm          = {573 - Neuroimaging (POF3-573)},
      pid          = {G:(DE-HGF)POF3-573},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:32150317},
      UT           = {WOS:000540009000014},
      doi          = {10.1002/hbm.24976},
      url          = {https://juser.fz-juelich.de/record/874445},
}